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Acinar cell carcinomas (ACCs) of the pancreas are rare pancreatic neoplasms accounting 
for about 1–2% of pancreatic tumors in adults and about 15% in pediatric subjects. They 
show different clinical symptoms at presentation, different morphological features, different 
outcomes, and different molecular alterations. This heterogeneous clinicopathological 
spectrum may give rise to difficulties in the clinical and pathological diagnosis with con-
sequential therapeutic and prognostic implications. The molecular mechanisms involved 
in the onset and progression of ACCs are still not completely understood, although in 
recent years, several attempts have been made to clarify the molecular mechanisms 
involved in ACC biology. In this paper, we will review the main clinicopathological and 
molecular features of pancreatic ACCs of both adult and pediatric subjects to give the 
reader a comprehensive overview of this rare tumor type.
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Background
Acinar cell carcinomas (ACCs) of the pancreas are very rare pancreatic neoplasms accounting 
for approximately 1–2% of pancreatic tumors in adults and about 15% in pediatric subjects 
(1). Although they are traditionally considered as a single tumor entity, several recent findings 
have demonstrated that they may show different clinical symptoms at presentation, different 
morphological features, different outcomes, and different molecular alterations. This heteroge-
neous clinicopathological spectrum may give rise to difficulties in the clinical and pathological 
diagnosis with consequential therapeutic and prognostic implications. The differential diagnosis 
from ductal adenocarcinomas is generally easy and is mainly based on morphology, whereas the 
distinction from pancreatic neuroendocrine tumors (PanNETs) is more difficult because of some 
similar morphological features. In addition, the differential diagnosis from solid pseudopapillary 
neoplasms and pancreatoblastomas may be problematic. The diagnostic hallmark of ACC is the 
immunohistochemical demonstration of acinar-specific products such as trypsin, lipase, amylase, 
and carboxyl ester lipase (CEL). The molecular mechanisms involved in ACC pathogenesis and 
progression are largely unknown, although in recent years, several attempts have been made to 
better understand the molecular pathology of such rare cancers. In general, the typical abnormalities 
of ductal adenocarcinomas including mutations in KRAS, DPC4, p16, and TP53 genes are absent 
or very rare in ACCs, while the better known pathogenetic mechanism includes abnormalities in 
the APC/β-catenin pathway (1).
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In this paper, we will review the main clinicopathological 
and molecular features of pancreatic ACCs to give the reader a 
comprehensive overview of this rare tumor type.
Acinar cell carcinoma in Adults
clinical Features
The average age of adult patients is approximately 59 years old 
(range 20–88 years). Males are more commonly affected with a 
male/female ratio of 2:1 (2–4). In the majority of cases presenting 
symptoms are non-specific and include abdominal pain, weight 
loss, vomiting, and nausea, which are related to tumor growth and/
or metastatic spread. Jaundice can be present, but it is much rarer 
than in ductal adenocarcinoma (2, 4). Patients with metastatic 
disease rarely show symptoms due to lipase hypersecretion, 
which include subcutaneous fat necrosis and polyarthralgia 
(5–7). Occasionally, patients, especially when young, may present 
increased alpha-fetoprotein (AFP) blood levels that should be 
considered as a suspicious marker of ACC in the presence of a 
pancreatic mass (8–11). Although most ACCs arise sporadically, 
rare cases diagnosed in the context of Lynch syndrome or familial 
adenomatous polyposis (FAP) have been documented (4, 12–14).
Macroscopy
Acinar cell carcinomas may arise in any portion of the pancreas. In 
a recently reported series in which macroscopic information was 
available for 58 ACCs, 22 tumors were in the head, 2 interested 
the head and the body, 5 the body, 12 the body and tail, 16 the tail, 
and 1 the entire pancreas (4). Tumors are generally large (average 
diameter of 8–10 cm), well circumscribed, and at least partially 
encapsulated. The cut surface generally appears homogeneous pink 
to tan, fleshy, or even friable in consistency (Figure 1). Hemorrhage 
and necrosis can be observed as well as cystic changes. A rare 
variant of ACC, exclusively characterized by variable-sized cysts, 
has been named acinar cell cystadenocarcinoma (15). Invasion of 
the tumor through the capsule is a common finding and in about 
50% of cases infiltration of the duodenum, large vessels, stomach, 
kidney, peritoneum, or spleen can also be observed (1, 4).
Histological Features
At scan magnification, tumors appear highly cellular with a lobular 
architecture and scant fibrous stroma (Figure 2). Necrosis is fre-
quent and in about 1/3 of cases is prominent. These morphological 
features can be useful for the differential diagnosis with the more 
common ductal adenocarcinomas that are generally less cellular, 
and show abundant fibrous stroma without or with focal necrosis 
(16). ACCs may have different histological features, ranging from 
acinar structures similar to normal pancreatic acini to solid growths 
composed of large sheets of poorly differentiated neoplastic cells. 
The acinar architectural pattern (Figure 3A) is characterized by 
cells forming structures resembling normal acini, sometimes with 
minute lumens. Cells are in a monolayer with basally located nuclei 
and have a moderate amount of granular eosinophilic cytoplasm. 
In some cases, the lumens can be dilated resembling glandular 
structures with cells sometimes arranged in multiple layers (glan-
dular pattern, Figure 3B). The trabecular pattern (Figure 3C) is 
characterized by trabecular structures formed by ribbons of cells 
FiGURe 1 | Macroscopic appearance of a well circumscribed and 
large acinar cell carcinoma of the pancreatic head.
strongly resembling the morphology of PanNETs. The solid pat-
tern (Figure 3D) is characterized by large sheets of cells without 
lumens that generally show large nuclei with dispersed chromatin 
and prominent nucleoli. With the exception of the typical acinar 
architecture, the other three patterns of growth may be difficult to 
interpret because they resemble those of other pancreatic neoplasms 
including solid pseudopapillary tumors (SPTs), PanNETs, and 
ductal adenocarcinomas. In these cases, immunohistochemistry is 
mandatory for the correct diagnosis (see the next paragraph). The 
most frequent morphologies are represented by acinar and solid 
growths, although a mixture of patterns can be frequently found 
within an individual ACC. Nuclei are generally uniform and a 
single nucleolus is characteristic. Mitotic rate is variable but gener-
ally high with a recently reported mean mitotic index of 14.63 (4). 
The cytoplasm is abundant, finely granular, and eosinophilic. It also 
contains several zymogen granules, which are periodic acid-Schiff 
(PAS) positive and resistant to diastase digestion (dPAS). In addi-
tion to these histological features, uncommon variants (Figure 4) 
have been described recently including oncocytic, spindle, and 
pleomorphic types (4). These rare variants should be taken into 
account because can give diagnostic difficulties, especially when 
looking at small bioptic specimens. They enter in the differential 
diagnosis with the more common oncocytic PanNETs (17) and 
undifferentiated carcinomas (18). Moreover, clear cell ACCs have 
been described anecdotally and recently observed by us in a liver 
metastasis and by Dr. Mounajjed (Mayo Clinic, Rochester, MN, 
USA) in a primary pancreatic ACC. These very uncommon ACC 
types enter in the differential diagnosis with clear cell PanNETs 
that can be observed sporadically or in association with both von 
FiGURe 2 | At scan magnification, most acinar cell carcinomas 
appear highly cellular with a lobular architecture and scant fibrous 
stroma. Abundant necrosis (right) is frequently observed. These 
morphological features can help in the differential diagnosis with the more 
common ductal adenocarcinoma that is generally less cellular, shows 
abundant fibrous stroma without or with focal necrosis.
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Hippel–Lindau disease and MEN1 (19, 20). Intraductal dissemina-
tion of ACC, characterized by intraductal polypoid growth, has 
been described (21–23). Interestingly, it has been suggested that 
ACCs showing this peculiar pattern of growth may be associated 
with less aggressive clinicopathologic features (23).
Histological Variant of ACC
Mixed acinar-neuroendocrine carcinomas
About one-third of ACCs shows a significant neuroendocrine 
component (>30%) and these cases are defined as mixed acinar-
neuroendocrine carcinomas (MANECs) (24). The neuroendocrine 
component is very difficult to identify morphologically on H&E 
stained sections and the use of immunohistochemistry employ-
ing antibodies directed against general neuroendocrine markers 
(chromogranin A and synaptophysin) is mandatory (Figure 5). 
However, it is worth noting that the survival rate of patients with 
ACCs and MANECs is the same (4).
Acinar cell cystadenocarcinoma
This rare variant presents as large, encapsulated multicystic lesion, 
measuring up to 25 cm in diameter. This neoplasm is composed 
of acinar and microglandular complexes as well as microcysts and 
macrocysts. The cysts are lined by cells with acinar morphology 
that are immunoreactive for pancreatic enzymes (15, 25, 26).
Mixed acinar-ductal adenocarcinoma
These neoplasms show both acinar and ductal differentiation 
(Figure  6) with prevalence of the acinar component in most 
cases (27). Some display a conspicuous mucinous component 
in association with acinar cells. Others show neoplastic glands 
surrounded by desmoplastic stroma similar to those of ordinary 
ductal adenocarcinoma, combined with a more solid component 
showing acinar differentiation.
Mixed acinar-neuroendocrine-ductal carcinoma
This is a very rare and not well-documented variant of ACC 
with multiple directions of differentiation. Histologically, these 
neoplasms are very similar to mixed acinar-ductal carcinomas: 
the neuroendocrine component was not identifiable histologically 
in the reported cases, but was detected with immunostaining for 
chromogranin A and/or synaptophysin (27, 28).
Ultrastructural Features
Tumor cells often form acinar-like complexes. Tumor cells con-
tain large electron-dense granules (Figure  7), abundant rough 
endoplasmic reticulum, well-developed Golgi complexes, and 
some mitochondria. Small microvilli are found in the apical 
surface. The majority of zymogen granules have a mean diameter 
of 400–500 nm and are homogeneous and round. The zymogen 
nature of these granules has been demonstrated with electron 
microscopy immunocytochemistry using anti-trypsin antibod-
ies (29). A second granule type, the irregular fibrillary granule, 
resembling the zymogen granules of the fetal pancreas has also 
been detected (2).
immunohistochemical Profile
Since the diagnostic hallmark of ACC is the demonstration of 
acinar differentiation, immunohistochemistry plays an indis-
pensable diagnostic role in the demonstration of specific acinar 
cell products. Traditional antibodies used to identify acinar 
differentiation are those directed against trypsin, lipase, amylase, 
and CEL, but it is well known that they significantly differ in 
terms of sensitivity (4, 30, 31). It has recently been suggested that 
the monoclonal antibody directed against the COOH-terminal 
portion of the BCL10 protein (clone 331.3), which recognizes the 
COOH-terminal portion of CEL, is a useful tool for detecting 
ACCs, because it is highly specific and sensitive (31). The BCL10 
immunoreactivity depends on the homology between the amino 
acid sequence 156 and 205 of the BCL10 protein (blast accession 
number: NP_003912.1) and the sequence between amino acid 
564 and 608 of CEL (blast accession number: NP_001798.2) and 
does not depend on the true presence of the BCL10 protein in 
acinar cells (31). The utility in detecting acinar differentiation of the 
antibody directed against the COOH-terminal portion of BCL10 
has been confirmed in further studies on both histological and 
cytological specimens (4, 32).
Among the various available antibodies, amylase is the least 
sensitive despite its wide expression in normal pancreatic acinar 
cells. Although the reason for this is not clear, amylase should not 
be considered as a useful diagnostic marker. In light of this obser-
vation, we suggest avoiding the use of the anti-amylase antibody in 
the diagnostic pathway of pancreatic ACCs, especially when only 
small bioptic specimens are available. Lipase expression, although 
more often found than amylase, is not detected in several cases. For 
this reason, we believe that lipase immunohistochemistry should 
only be included in the panel used to study surgical specimens for 
completeness. Our and other studies show that antibodies directed 
against trypsin and BCL10 (Figure  8) are the best in terms of 
FiGURe 3 | Acinar cell carcinomas may have different histological 
features. The acinar architectural pattern (A) is characterized by cells forming 
structures resembling normal pancreatic acini, sometimes with minute 
lumens. Cells are in a monolayer with basally located nuclei and have a 
moderate amount of granular eosinophilic cytoplasm. The glandular pattern 
(B) is characterized by proliferation of cells, sometimes arranged in multiple 
layers, forming glandular structures. The trabecular pattern (c) is 
characterized by trabecular structures formed by ribbons of cells strongly 
resembling the morphology of pancreatic neuroendocrine tumors. The solid 
pattern (d) is characterized by large sheets of poorly differentiated cells 
without lumens that generally show large nuclei with dispersed chromatin and 
prominent nucleoli.
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sensitivity (2, 4, 30, 31). In our routine practice, we use both trypsin 
and BCL10 antibodies because it has been demonstrated that 15 
and 4% of ACCs may be BCL10 and trypsin negative, respectively 
(4). In our hands, the simultaneous use of both antibodies allows 
the detection of approximately 100% of ACCs, therefore, avoiding 
the lack of recognition of those cases that only express one of these 
two markers.
Scattered chromogranin A and/or synaptophysin positive neu-
roendocrine cells can be observed in several ACCs (Figure 9A). 
In about one-third of cases, they represent more than 30% of 
neoplastic cells and such ACCs are currently defined as MANECs 
following the criteria proposed in the 2010 WHO classification of 
tumors of the digestive system (24).
In addition to the acinar cell markers described above, ACCs 
may also express cytokeratin (CK) 7 and CK19 (Figures 9B,C) (4, 
33, 34), traditionally known as markers of ductal adenocarcinomas. 
The knowledge that these two CKs can be expressed in at least a 
subset of ACCs should be taken into account during the diagnostic 
pathway for the differential diagnosis with ductal adenocarcinoma 
that should not be considered only on the basis of CK7 and CK19 
immunoreactivity, independently of the morphological context.
Immunoreactivity for PDX1 (Figure 9D), a homeobox tran-
scription factor involved in the regulation of pancreatic develop-
ment, has recently been reported in ACCs (4, 35). This marker 
does not seem correlated with prognosis and it is not a marker of 
ACC when diagnosing a primary pancreatic neoplasm. It may be 
useful in the diagnostic pathway of metastatic lesions to document 
a possible pancreatic origin.
Nuclear expression of β-catenin (Figure 9E) can be found in 
about 10% of ACCs. This confirms that alterations in the β-catenin 
pathway are involved in a subset of ACCs (4, 36, 37). Its expression 
should also be considered for the differential diagnosis with SPTs 
(see the next paragraph).
Although the role of p53 in the tumorigenesis and progression 
of ACCs still remains to be elucidated and p53 nuclear immuno-
reactivity has not been found in some investigations (36, 38, 39), 
we have recently demonstrated that a subgroup of ACCs strongly 
express p53 (Figure 9F). Interestingly, patients with tumors show-
ing more than 50% of p53-positive cells showed a trend of worse 
survival rate than those with tumors lacking or expressing p53 in 
<50% of neoplastic cells (4). However, further studies are needed 
to confirm the prognostic role of p53 expression.
differential diagnosis
The differential diagnosis between ACCs and other pancreatic 
tumor types should be based, first, on morphological features 
and, then, on immunohistochemical analyses, which are useful 
in demonstrating acinar differentiation.
FiGURe 5 | Mixed acinar-neuroendocrine carcinomas (MAnecs)  
are composed of both acinar and neuroendocrine components  
and each must represent at least 30% of the tumor tissue. The 
neuroendocrine component is very difficult to identify morphologically on 
H&E stained sections (A). The use of immunohistochemistry  
employing antibodies directed against general neuroendocrine  
[(B) chromogranin A] and acinar markers [(c) BCL10] is mandatory for  
the diagnosis.
FiGURe 4 | Uncommon histological features of pancreatic acinar cell carcinomas include oncocytic cells (A), spindle cells (B), pleomorphic cells (c), 
and clear cells (d).
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The differential diagnosis with ductal adenocarcinoma is 
generally easy because of the different morphology of these two 
cancer types. However, in some particular cases of ACC with 
unusual morphology (spindle cell, clear cell, and pleomorphic 
cell variants), the use of immunohistochemistry is mandatory for 
the correct diagnosis. ACCs express acinar markers (trypsin and 
BCL10 are the most sensitive and specific), which are lacking in 
ductal adenocarcinoma. It is worth noting that ACCs may express 
CK7 and CK19, which are not consequently specific indicators 
of a ductal origin. For this reason, the value of CK7 and CK19 
expression in a pancreatic tumor should be evaluated with caution.
The differential diagnosis with PanNETs may be more dif-
ficult because of some morphological similarities between 
ACCs and PanNETs. However, the presence of a high-mitotic 
index, abundant necrosis, clearly evident nucleoli in appar-
ently well to moderately differentiated cells with abundant 
eosinophilic cytoplasm, should give rise to the suspicion of an 
ACC. Immunohistochemistry is useful, but it must be used with 
caution. The use of general neuroendocrine markers including 
chromogranin A and synaptophysin alone may be risky because 
several ACCs show at least scattered neuroendocrine cells, which, 
in 30% of cases, are particularly abundant (MANECs). For this 
FiGURe 7 | At the ultrastructural level, tumor cells contain large 
electron-dense granules, abundant rough endoplasmic reticulum, 
well-developed Golgi complexes, and some mitochondria.
FiGURe 6 | (A) Mixed acinar-ductal adenocarcinoma is a neoplasm 
showing both acinar (top right corner) and ductal differentiation. 
Neoplastic glands are generally surrounded by a desmoplastic  
stroma similarly to ordinary ductal adenocarcinomas. The acinar 
component is easily identifiable using acinar cell markers including  
BCL10 (B).
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reason, if an ACC is suspected, the demonstration of acinar cell 
products in mandatory.
The differential diagnosis with SPT may be difficult, although 
this tumor is more frequent in females and rarely shows abun-
dant necrosis. SPTs typically show nuclear immunoreactivity for 
β-catenin and strong expression of CD10 that, however, can also 
be found in about 10 and 60% of ACCs, respectively (4, 33). For 
this reason, these two markers should not be used alone but in 
association with acinar-specific ones such as trypsin and BCL10.
Pancreatoblastoma (PB) is a malignant epithelial neoplasm 
showing multiple lines of differentiation including acinar 
differentiation. Consequently, the differential diagnosis with 
ACC may be difficult. The presence of squamoid nests in PB 
is the histological hallmark that distinguishes between the two 
entities.
Acinar cell cystadenocarcinoma needs to be distinguished 
from acinar cell cystadenoma, which is a rare benign cystic 
neoplasm lined by cells showing acinar differentiation. In acinar 
cell cystadenocarcinoma, the epithelium lining the cysts is more 
complex and tumor cells are less well polarized, atypical with a 
well evident single nucleolus. Moreover, areas of solid growth with 
necrosis and infiltration into the stroma support the diagnosis of 
malignancy (40).
In addition to the differential diagnosis with other primary 
pancreatic neoplasms, liver metastases from pancreatic ACCs need 
to be distinguished from primary liver ACCs (41, 42). Since the 
morphological features are identical between the two entities, an 
accurate radiological investigation and intra-operative examination 
are mandatory. It is worth noting that primary liver ACCs are gener-
ally solitary neoplasms, while metastases from pancreatic ACCs are 
generally multiple and associated with metastatic spread outside the 
liver in most of cases (4, 42). This clinical context should be taken 
into account when diagnosing a suspected primary liver ACC.
Molecular Pathology
The molecular mechanisms involved in the onset and progres-
sion of ACCs are poorly known, although in the last 10 years, 
several attempts have been made, using different technical 
methods, to better understand the molecular biology of such 
cancers. The main difficulty in studying the molecular profile 
of ACCs is their rarity and, consequently, the difficulty in col-
lecting a significantly large number of cases. In general, the 
most common molecular alterations of ductal adenocarcinomas 
including mutations of KRAS, TP53, DPC4, and p16 genes 
are absent or rare in ACCs, while losses of chromosome 11p, 
alterations in the APC/β-catenin pathway, and loss of DCC 
expression have been observed in several cases. In the present 
section, we will review the molecular alterations investigated 
in adult ACCs (Table 1).
KRAS Mutations
While KRAS mutations are commonly found in ductal adenocar-
cinomas (43), they are exceedingly rare in ACCs. KRAS mutations 
FiGURe 8 | Antibodies directed against trypsin (A) and BcL10 (B) are the best in terms of sensitivity in detecting acinar cell carcinoma. The 
immunoreactivity is cytoplasmic and strong.
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have been investigated in 9 studies including 196 ACCs/MANECs 
and they were only found in 2 cases, representing 1% (37, 38, 
43–49).
EGFR Mutations
Mutational analysis of EGFR (exons 18–21) has been investigated 
recently in 57 ACCs and no mutations have been found (48). In 
the same study, EGFR immunoreactivity at the cell membrane 
level was observed in 19/45 (42%) cases. The EGFR status may 
be interesting for the possible use of anti-EGFR-directed therapy. 
However, there is currently not enough data to suggest the possible 
response to this target therapy.
BRAF Alterations
BRAF mutations have been investigated in only two studies 
using either whole-exome sequencing analysis (47) or immuno-
histochemistry with the anti-BRAF V600E antibody (48). BRAF 
mutations were found in two mixed acinar-ductal carcinomas 
and in only 1 out of 17 pure ACCs (47). Among the 42 immu-
nohistochemically investigated ACCs none were positive for the 
anti-BRAF antibody (48). Although BRAF mutations are very rare, 
it has recently been demonstrated that about 23% of ACCs harbor 
rearrangements involving BRAF and RAF1 and the most prevalent 
fusion was SND1-BRAF. Interestingly, SND1-BRAF transformed 
cells were sensitive to treatment with MEK inhibitors (trametinib), 
suggesting a new therapeutic approach to ACCs (49).
p16 Mutation
p16 mutation does not seem to be involved in ACCs, although 
only a few cases have been investigated. Moore and coworkers did 
not find any p16 mutations in 6 ACCs (43). Although these data 
suggest that p16 is not involved in ACCs tumorigenesis, further 
studies enrolling many more cases are needed to finally clarify 
the role of this gene.
DPC4/SMAD4 Alterations
Although traditionally DPC4/SMAD4 mutations have been believed 
to be absent in ACCs, recent investigations have demonstrated 
mutations or truncations of these genes in at least a subset of cases 
using different methodological approaches including mutational 
analysis (43), whole-exome sequencing analysis (47), NGS-based 
genomic profiling (49), and immunohistochemistry (36, 39, 43, 
46). DPC4/SMAD4 mutations were found in 11/59 (18.6%) ACCs/
MANECs (47, 49), while lack of DPC4 immunoreactivity was 
observed in 1 out of 35 (2.8%) cases investigated (36, 39, 43, 46).
TP53 Mutations and p53 Immunohistochemical 
Expression
p53 expression in ACCs was immunohistochemically inves-
tigated for the first time in 1993 by Hoorens and coworkers 
using a polyclonal antibody, which did not identify any nuclear 
immunoreactivity (38). Since then three other studies, using 
the monoclonal DO-7 or DO-1 antibodies, have investigated 
the immunohistochemical nuclear expression of p53, which 
was found in 10/85 (11.7%) cases (4, 36, 39). However, the 
comparison of such investigations is quite difficult because of the 
different antibodies employed, different immunohistochemical 
methods, and different cut-offs used to define a tumor as posi-
tive. We have recently used a very high cut-off (50% of positive 
cells) to consider a tumor as positive. This choice was derived 
from the fact that it has been demonstrated that high cut-off 
of p53 protein expression accurately identifies gene mutation, 
thus consistently reducing false-positive immunoreactivity (4). 
Because the first published papers, mainly based on immuno-
histochemical findings, did not demonstrate p53 alterations, 
it has traditionally been considered that, unlike pancreatic 
ductal adenocarcinomas, ACCs do not harbor TP53 mutations. 
However, after accurately analyzing the seven studies in which 
TP53 mutations were investigated, it clearly appears that it is 
not as rare as believed initially. Indeed, TP53 mutations have 
been identified in 12 out of 133 (12%) ACCs (43, 44, 46, 47, 49, 
51, 52). In addition to mutations, TP53 gene loss has also been 
documented in different studies (43, 49, 52, 53). Interestingly, 
p53 immunoreactivity showed a trend of poor survival (4) and 
the concomitant presence of both TP53 mutations and gene loss 
correlated with a worse prognosis (52). However, further studies 
are needed to clarify the potential role of p53 in the progression 
and aggressiveness of ACCs.
FiGURe 9 | Acinar cell carcinomas frequently show scattered 
chromogranin A-positive neuroendocrine cells (A), but for the 
diagnosis of MAnec they must represent at least 30% of the tumor 
tissue (see Figure 5). Acinar cell carcinomas may also express cytokeratin 
7 (B) and cytokeratin 19 (c), which are traditionally known markers of  
ductal adenocarcinomas. PDX1 immunoreactivity (d) is observed in  
about 90% of cases, while nuclear positivity for β-catenin (e) in about  
15% of cases. Strong nuclear immunoreactivity for p53 (F) can be  
found in about 30% of carcinomas and its prognostic meaning is not  
clear, to date.
June 2015 | Volume 2 | Article 418
La Rosa et al. Pancreatic acinar cell carcinoma
Frontiers in Medicine | www.frontiersin.org
BRCA2 Alterations
BRCA2 mutations were found in 4/30 ACCs (47, 50). In the study 
by Furukawa et al., the reported BRCA2 mutations were either 
somatic or germline premature termination mutations associ-
ated with loss of the normal wild-type allele and lack of BRCA2 
immunoreactivity. Interestingly, one of these patients presented 
complete remission of liver metastases after cisplatinum-based 
chemotherapy (50). Alterations of BRCA2 including truncation 
and loss were identified in 6/29 and 1/3 ACCs, respectively (49, 
53). In one study, BRCA2 amplification has been found in one out 
of five ACCs (46).
APC/β-Catenin Pathway Alterations
Alterations in the APC/β-catenin pathway have been well-
documented and include mutations of both APC and CTNNB1 
genes. APC mutations have been investigated in 4 studies includ-
ing 99 ACC/MANECs. They were found in eight cases (8%). 
CTNNB1 mutations have been demonstrated in 5/70 (7%) ACC/
MANECs investigated in three different studies (36, 37, 49), 
while abnormal nuclear β-catenin immunoreactivity has been 
documented in 5/39 (12.8%) cases investigated in two studies (4, 
46). However, it has recently been demonstrated that the most 
frequent alterations of the APC gene are mainly due to gene loss 
TABLe 1 | summary of gene alterations in pancreatic acinar cell 
carcinomas and mixed acinar-neuroendocrine carcinomas described in 
the medical literature.
Gene Mutation Reference
KRAS 2/196 (1%) (37, 38, 43–49)
EGFR 0/57 (48)
BRAF 1/17 (5.9%) (47)
p16 0/6 (43)
BRCA2 4/30 (47, 50)
DPC4/SMAD4 11/59 (18.6%) (47, 49)
TP53 12/133 (12%) (43, 44, 46, 47, 49, 51, 52)
APC 8/99 (8%) (36, 37, 47, 49)
CTNNB1 5/70 (7%) (36, 37, 49)
Gene deletion Reference
TP53 46/187 (25%) (39, 43, 45, 47–49, 52, 53)
BRCA2 1/3 (33%) (53)
APC 12/25 (48%) (37)
Gene Methylation Reference
APC 24/43 (56%) (37)
RASSF1 26/43 (60%) (37)
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and/or promoter hypermethylation rather than APC mutations. 
APC loss and hypermethylation were found in 48 and 56% of ACC/
MANECs, respectively, whereas APC mutations were detected in 
only 7% (37). Interestingly, loss and methylation of APC gene 
were also found in normal appearing non-neoplastic pancreatic 
tissues adjacent to ACCs, suggesting that the “field cancerization” 
phenomenon, which has been described in prostate, head and 
neck, colon, esophageal, lung, and breast carcinomas (54) may 
also exist for pancreatic ACCs (37). Another interesting aspect of 
APC alterations in ACCs is the well-known correlation between 
chromosome instability and loss of APC function, which, being 
involved in mitosis regulation, leads to polyploidy. Interestingly, 
low APC mRNA levels were directly correlated to high frequency 
of copy number alterations and chromosome instability (37, 48).
In addition to these direct evidences, which demonstrate 
the role of APC gene in the pathogenesis of pancreatic ACCs, 
there are additional indirect experimental findings that suggest 
that this gene is involved in the pathogenesis of such carcinomas 
and, in general, in the biology of normal pancreatic acinar cells. 
APC gene inactivation, in pancreatic epithelial cells of mouse 
embryos, induced pancreatomegaly due to selective proliferation 
of acinar cells between birth and 6 months of age (55). Moreover, 
mice constitutively null for functional p53 and heterozygous for 
APC mutations developed dysplastic acinar foci and ACCs (56). 
Whereas in DNA methyltransferase (Dnmt) 1 hypomorphic mice, 
reduced methylation of tumor suppressor genes, mainly APC, leads 
to a reduction of pancreatic ACC development (57).
Chromosomes Abnormalities
The first description of chromosome abnormalities in ACCs was 
reported in 2002 by Abraham and coworkers who described the 
allelic loss of chromosome 11p in 50% of the cases they investigated 
(36). Since then, chromosome gains and losses have been investi-
gated using different molecular approaches including comparative 
genomic hybridization (CGH), fluorescence in situ hybridization 
(FISH), multiple ligation probe amplification (MLPA), loss of 
heterozygosis (LOH) analysis using PCR, and whole-exome 
sequencing analysis (37, 39, 47, 48, 53). From the global analysis 
of the findings reported in the literature, it appears that pancreatic 
ACCs show chromosome instability characterized by high degrees 
of allelic loss and gains. The more frequently involved regions as 
losses included 1p, 3p, 5q, 6q, 8p, 9p, 11, 17p, and 18q, while the 
gained regions mainly were 1q, 7, 8q, 12, 17q, and 20q (37, 45, 
47, 48). Interestingly, a hierarchical clustering of CGH findings 
did not find differences between pure ACCs, cystic ACCs, and 
MANECs indicating that these subtypes have the same cytogenetic 
background. Moreover, although some cytogenetic similarities 
between ACCs and ductal adenocarcinomas have been observed, 
the cytogenetic profile of ACCs is globally different from that 
of ductal adenocarcinomas confirming that these two types of 
exocrine pancreatic cancers are two different entities also in terms 
of cytogenetic alterations (48). Several chromosomal imbalances 
have also been associated with tumor size and metastatic spread 
suggesting a possible role of chromosomal abnormalities in the 
progression and aggressiveness of ACCs. A very recent and inter-
esting finding regards the amplification of c-MYC, located at the 
8q24 locus, which was found in 17% of ACCs, even if its role in 
biological aggressiveness remains to be clarified (48). Loss of 18q 
was one of the most frequent chromosome abnormalities found 
in a recent study on ACC (48). This loss was correlated with the 
loss or significant reduction of deleted in colorectal carcinoma 
(DCC) protein and has been considered as an early step in the 
development of ACCs.
Methylation Profile
Aberrant methylation of CpG islands is a well-known mechanism 
associated with the silencing of cancer-related genes in several can-
cers including pancreatic adenocarcinomas (58, 59) and PanNETs 
(60). In the literature, there is only one study, which, analyzing 
the promoter methylation status of 34 tumor suppressor genes, 
evaluated the methylation profile of ACCs (37). In general, ACCs 
showed low levels of hypermethylation and no tumors character-
ized by concerted hypermethylation at multiple loci were identified 
among 55 ACC/MANECs investigated. Consequently, the so-called 
“CpG island methylator phenotype (CIMP)” described not only in 
colorectal cancers but also in pancreatic ductal adenocarcinomas 
and PanNETs (60, 61) seems not to be present in pancreatic ACCs. 
However, some genes, including RASSF1 and APC, frequently were 
found to be methylated. Interestingly, RASSF1 promoter methyla-
tion was found also in non-neoplastic pancreatic tissues adjacent 
to ACCs (37).
Microsatellite Instability
Acinar cell carcinoma is an unusual tumor found in the context 
of Lynch syndrome with only four cases described in the litera-
ture (12, 13, 62). However, microsatellite instability has been 
evaluated in five different studies since Abraham and cowork-
ers described three unstable ACCs in 2002 (13, 36, 46, 48, 62). 
Microsatellite instability has been investigated in a total of 159 
ACCs and 13 of them (8.2%) were found to be unstable. The 
relationship between MSI and MLH1 methylation has never been 
investigated in pancreatic ACCs. Unstable ACCs did not show 
peculiar morphological features useful for their identification 
FiGURe 10 | Acinar cell carcinoma in a 1-year-old boy characterized 
by a trabecular growth (A) resembling that of a pancreatic 
neuroendocrine tumor. However, tumor cells are strongly immunoreactivity 
for trypsin (B).
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(13). It is also worth noting that there are not enough clinico-
pathological data demonstrating a different survival of unstable 
ACCs, compared to stable ones. Furthermore, there are no 
clinical trials suggesting a different therapeutic approach to this 
subset of ACCs to date.
Prognostic Factors
The prognostic meaning of several morphological features, 
immunohistochemical markers, and molecular abnormalities 
has been investigated in recent years. Some markers, including 
vascular invasion, perineural infiltration, CK19 immunoreactivity, 
and p53 expression in more than 50% of neoplastic cells, showed 
a trend of worse survival but not reaching statistical significance 
(4). Other markers such as tumor size, lymph node and distant 
metastases, RASSF1 methylation, and STK11 and TP53 copy 
number alterations were statistically associated with prognosis 
in univariate analysis (4, 37). However, in multivariate analysis, 
only UICC stage proved to be an independent prognostic factor. 
Interestingly, the best prognostic stratification of patients was 
observed by grouping together stage I with stage II, and stage 
III with stage IV, suggesting a simplification of UICC staging for 
pancreatic ACCs (4).
Acinar cell carcinoma in infancy
epidemiology
Exocrine pancreatic tumors including ductal adenocarcinomas, 
ACCs, SPTs, and PBs are rare in children and adolescents. The 
rarity of such tumors has been the cause of the small number 
of cases analyzed in collective studies (63–67). The study with 
the largest number of patients examined the SEER data and 
contained significant demographic and statistical analyses (63). 
The incidence rate of pancreatic tumors in 0- to 19-year-old 
subjects was 0.018/100,000 inhabitants per year (adjusted to 
the 2000 US standard population) in the SEER database, 0.20 in 
the TREP report and 0.018 in a German study (54, 63, 67). The 
incidence rates, age adjusted to the 2000 US standard population 
for tumor histology, were 0.003 for ductal adenocarcinomas, 0.003 
for ACCs, 0.004 for PBs, 0.005 for SPTs, and 0.007 for PanNETs 
(63). From the data reported in three studies, SPTs represented 
the most frequent pancreatic neoplasm in pediatric population 
accounting for 29.8% of the cases, followed by PanNETs (24.7%), 
PBs (23.7%), ACCs (7.2%), ductal adenocarcinomas (7.2%), and 
non-epithelial neoplasms (7.2%) (63–65). From the same studies, 
it appeared that 86.2% of SPTs occurred in females whereas males 
had a higher incidence of ductal adenocarcinomas (71.4%). Of 
the 23 PBs, 16 (69.6%) were diagnosed in patients younger than 
10 years, while 96.5% of SPTs, 71.4% of ductal adenocarcinomas, 
and 54.1% of PanNETs occurred in children 10 years or older. 
Among the 29 cases of pediatric ACCs reported in 20 papers from 
1970 to 2014, there were 18 males and 11 females with an average 
age of 9.57 years (range 3–16 years); 14 carcinomas occurred in 
children 10 years or older.
Localization
Pediatric ACCs may involve any portion of the pancreas but 
are more common in the tail (41% of cases), followed by the 
head (32%), the body (13.5), the body-tail (9%), and the head- 
body (4.5%).
clinical Features
Most cases present with vague abdominal pain or discomfort and 
abdominal swelling or mass. Jaundice is not a part of the usual 
clinical presentation. Some children may have nausea and vomiting 
or mild fever and anemia. It must be underlined that, unlike in 
adult cases, none of the ACC reported in children presented with 
polyarthralgia, panniculitis, or subcutaneous fat necrosis due to 
lipase release by the tumor into the circulation (2). Serum AFP 
levels were elevated in all pediatric cases of ACCs in which it 
was measured (10, 67) and it has been hypothesized that AFP 
production in pancreatic neoplasms is related to acinar differentia-
tion (10). In 3 of 29 pediatric ACCs, the most significant clinical 
manifestation was Cushing’s syndrome due to ectopic production 
of ACTH by tumor cells (11, 68, 69).
Macroscopy
Macroscopically, pediatric ACCs are usually large at the time 
of presentation, with an average diameter of 11.8  cm (range 
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3.2–20 cm). They are well circumscribed, fleshy, pink to tan, and 
generally contain areas of necrosis and/or hemorrhage. Cystic 
variants have been described less frequently (70).
Histological and immunohistochemical Features
Acinar cell carcinomas in children show the same histological 
features and immunohistochemical reactivity of those of adults 
(Figure  10). Among the 29 cases reported in the literature, 22 
were pure ACCs, 4 MANECs, 1 acinar cell cystoadenocarcinoma, 
1 mixed acinar-ductal carcinoma, and 1 mixed acinar-neuroendo-
crine-ductal adenocarcinoma. The cases of ACCs associated with 
Cushing’s syndrome were characterized by a surprisingly scant 
neuroendocrine component weakly immunoreactive for ACTH 
and general neuroendocrine markers including chromogranin A 
and synaptophysin (11, 68, 69).
differential diagnosis
Acinar cell carcinoma in the pediatric population may closely 
resemble a PanNET and has overlapping features with PB and 
SPT. Squamoid nests, absent in ACC, are considered the ele-
ments required for the diagnosis of PB (71). Unlike ACCs that 
show only focal or zonal expression of neuroendocrine markers, 
PanNETs show diffuse expression of these markers and lack the 
expression of trypsin, chymotrypsin, lipase, and BCL10. In cases 
of SPTs lacking the characteristic pseudopapillary structures and 
mimicking ACCs, the immunohistochemical expression of CD10 
and vimentin, the nuclear labeling of β-catenin, and the negativity 
for exocrine enzymes favor the diagnosis of SPT.
Molecular Pathology
The only study examining molecular alterations in ACCs in 
children is by Abraham and coworkers (36): in two pediatric 
cases, no allelic loss of chromosome 11p and no mutations 
in the APC/β-catenin pathway were detected, unlike some 
of the adult cases. High frequencies of both allelic loss of 
 chromosome 11p and mutations in the APC/β-catenin pathway 
were detected in PBs.
Prognosis and Predictive Factors
Metastases have been reported in 41% of the 29 pediatric ACCs 
described in the literature, being loco-regional in 26% of the 
cases and distant in 22%. Patients underwent only surgical 
resection in 43% of cases, surgical resection combined with 
chemotherapy and/or radiotherapy in 36% of cases and pallia-
tive chemotherapy in 21% of cases. After chemotherapy, 45% 
of the patients were alive with no evidence of disease with an 
average follow-up time of 25.5 months (from 3 to 132 months), 
13.7% were alive with disease with an average follow-up time of 
14.7 months, 27.5% died of disease with an average survival of 
34.4 months. The above reported data confirm the suggestion 
that pediatric patients with ACCs may have a better prognosis 
than adults (2).
In conclusion, ACC is a very rare pancreatic neoplasm in 
children that must be distinguished from PanNET, PB, and SPT. 
The clinical evolution of this neoplasm in children seems to be 
better than that observed in adults. Pediatric pathologists should 
consider this neoplasm in the differential diagnosis of primary 
pancreatic masses in children.
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